Sales & Marketing News | pharmaphorum

News

J&J adds to IL-23 options in Crohn's after FDA approval

J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.

News

UK is becoming an 'outlier' for pharma, hitting investment

UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.

News

Novartis sheds staff as Entresto patent expiry looms

Novartis will cut 427 jobs this year in the US as it prepares for the loss of market exclusivity for its blockbuster heart failure therapy Entresto.

News

Novo Nordisk returns to ABPI fold after two-year suspension

Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."

News

FDA chooses flu vaccine strains despite cancelled meeting

The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season – without the input of its external advisors.

News

Pharma furious as UK Statutory Scheme rebate rate soars

The UK pharma sector has reacted with consternation to the government's proposal to raise the Statutory Scheme rate to 32.2% in the last half of 2025.

J&J adds to IL-23 options in Crohn's after FDA approval

UK is becoming an 'outlier' for pharma, hitting investment

Novartis sheds staff as Entresto patent expiry looms

Novo Nordisk returns to ABPI fold after two-year suspension

FDA chooses flu vaccine strains despite cancelled meeting

Pharma furious as UK Statutory Scheme rebate rate soars

Immunovant's thyroid eye disease drug flunks pivotal trials

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks